Omeros Corporation (NASDAQ:OMER) Stock Has Average Target Price of $30.33 According to Analysts

Omeros Corporation (NASDAQ:OMER) has received an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $30.33.

A number of brokerages have weighed in on OMER. HC Wainwright restated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Weiss Ratings raised Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $22.00 target price on shares of Omeros in a research report on Wednesday, October 14th. Finally, Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th.

Omeros Stock Performance

OMER stock opened at $17.83 on Thursday. The firm has a market cap of $1.29 billion, a PE ratio of 13.93 and a beta of 2.57. The firm’s fifty day moving average is $18.49 and its 200 day moving average is $13.49. Omeros has a one year low of $6.24 and a one year high of $21.24.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analysts’ expectations of $12.69 million. Research analysts predict that Omeros will post -0.37 earnings per share for the current fiscal year.

Insider Transactions at Omeros

In other Omeros news, VP Peter B. Cancelmo sold 25,000 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $18.54, for a total transaction of $463,500.00. Following the sale, the vice president directly owned 200 shares in the company, valued at $3,708. This represents a 99.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arnold C. Hanish sold 10,000 shares of the stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $18.95, for a total transaction of $189,500.00. Following the sale, the director directly owned 5,000 shares in the company, valued at $94,750. This represents a 66.67% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 105,906 shares of company stock valued at $1,989,705. Insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC boosted its holdings in Omeros by 75.3% in the third quarter. Sterling Capital Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 758 shares during the period. GK Wealth Management LLC purchased a new stake in Omeros during the 3rd quarter worth about $65,000. Assetmark Inc. purchased a new stake in Omeros during the 1st quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Omeros in the 3rd quarter valued at about $70,000. Finally, International Assets Investment Management LLC raised its position in Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 800 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.